Singapore markets open in 5 hours 37 minutes
Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.85 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
59,789.11 -2,220.73 (-3.58%) CMC Crypto 200
1,292.77 -42.15 (-3.16%)
PTCT Aug 2024 35.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:13AM EDT
| Previous close | 3.7100 |
| Open | 4.0300 |
| Bid | 0.0000 |
| Ask | 4.7000 |
| Strike | 35.00 |
| Expiry date | 2024-08-16 |
| Day's range | 3.7100 - 4.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksPTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
PR NewswireCHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission (EC) for re-review.
ZacksPTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
© 2024 Yahoo. All rights reserved.